Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-11-24
2000-12-12
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
51425506, 544353, 544354, 544356, 544344, A61K 31498, C07D24136
Patent
active
061599786
ABSTRACT:
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
REFERENCES:
patent: 3272824 (1966-09-01), Ebetino et al.
patent: 4661499 (1987-04-01), Young et al.
patent: 5336518 (1994-08-01), Narayanan et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 5605696 (1997-02-01), Eury et al.
patent: 5637113 (1997-06-01), Tartaglia et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5650514 (1997-07-01), Stoltefuss et al.
patent: 5700286 (1997-12-01), Tartaglia et al.
patent: 5700823 (1997-12-01), Hirth et al.
patent: 5760066 (1998-06-01), Tang
patent: 5824049 (1998-10-01), Ragheb et al.
Maguire et al., A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives, J. Med. Chem., 1994, 37, 2129-2137.
Preparation of 3-(N-aryl-and N-heterocyclaminomethyl)indole derivatives having excellent efffect . . . nerve growth factor, Chem. Abstracts, vol. 125, No. 15, p. 1213, col. 2, No. 195667C.
Rice et al., Specific Inhibitors of Platelet-Derived Growth Factor or Epidermal Growth Factor Receptor Tyrosine Kinase Reduce Pulmonary Fibrosis in Rats, Am. J. Pathol., 1999, 155(a), pp. 213-221.
Heldin et al., Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor, Physiological Reviews, 1999, 79(4), pp. 1283-1316.
Loriga et al., Quinoxaline Chemistry. Part 4. 2-(R)-Anilinoquinoxalines as Nonclassical Antifolate Agents., II Famaco, 50 (5), 289-301 (1995).
Kim et al., A Selective Synthesis of Isoxazolo [2,3-1]quinoxalines and Pyrrolo[1,2-a]quinoxalines by 1, 3-Dipolar Cycloaddition Reaction, Journal of the Korean Chemical Society, vol. 34, No. 5, 1990, pp. 469-475. Abstract.
Rewcastle et al., Tyrosine Kinase Inhibitors, J. Med. Chem. 1995, 38, 3482-3487.
Newbold et al., The Oxidation of 2-Hydroxyquinoxaline and its Derivatives with Hydrogen Peroxide, J. Chem Soc., 1948 (519-522).
Makino et al., The Syntheses of Novel 2-(2-Quinoxalinyl) Pyridazine-3(2H)-Ones, Heterocycles, vol. 23, No. 10, 1985, pp. 2603-2611.
Burke, Jr., Protein-Tyrosine Kinases: Potential Targets for Anticancer Drug Development, Stem Cells, 1994: 12:1-6.
N-Quinoxalinylanilines, Chemical Abstracts, vol. 103, 1985, 160539f.
Lin et al., Studies on antiarrhythmics, Chemical Abstracts, vol. 96, 1982, 122728w.
Takase et al., Preparation of N-containing heterocyclic compounds as phosphodiesterase inhibitors, Chemical Abstracts, vol. 119, 1993, 203427t.
Hirth et al., , Derwent computer search, 1995, 861279.
Derwent Information Ltd., 1982-64774E JP57102871 Abstract.
Derwent Information Ltd., 1985-168512 Abstract.
Shawyer et al., Inhibition of Platelet-derived Growth Factor-mediated Signal Transduction and Tumor Growth by N-[4-(Trifluoromethyl10-phenyl]5-Methylisoxazole-4-carboxamide, Clinical Cancer Research, vol. 3, 1167-1177, Jul. 1997.
Klutchko et al., 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones., J. Med. Chem., 1998, 41, 3276-3292.
Sakata et al., , Chem. Abstract, Nippon Noyaku Gakkasishi, 19(1), 61-7, (1985); 109577.
Zellner et al. "Synth.v.Chino.-Derv.";Helv.Chim.Acta49/2,913(1966)/CA64:15882d, Feb. 1966.
Zellner et al, Chemical Abstracts, vol. 64,#15882, Feb. 1966.
Maguire Martin P.
Myers Michael R.
Persons Paul E.
Spada Alfred P.
Aventis Pharmaceuticals Product, Inc.
Butch Peter
Newman Irving
Patel Sudhaker B.
Shah Mukund J.
LandOfFree
Quinoline and quinoxaline compounds which inhibit platelet-deriv does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline and quinoxaline compounds which inhibit platelet-deriv, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline and quinoxaline compounds which inhibit platelet-deriv will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-217925